<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342510</url>
  </required_header>
  <id_info>
    <org_study_id>2010-0139</org_study_id>
    <nct_id>NCT01342510</nct_id>
  </id_info>
  <brief_title>Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol</brief_title>
  <official_title>The Evaluation of the Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the introduction of propofol into routine anesthesia practice, the phenomena of pain on
      injection has plagued anesthesia providers. Propofol, an unstable phenol, triggers the
      release of bradykinin on injection. This release causes a painful burning sensation in the
      patient at the site of injection. Anesthesia providers have attempted a large number of
      remedies to prevent this pain on injection. Previously explored ideas include injecting
      propofol into larger veins, warming of the hand with hot packs, and intravenous pretreatment
      with numerous other medications. Currently, pretreatment with lidocaine is commonly
      administered to prevent propofol injection pain. No studies to date have looked at the
      combination of lidocaine and magnesium in a single syringe for the pretreatment of pain on
      injection caused by propofol. In addition, the administration protocols that have been
      studied thus far do not mirror clinical practice at the University of Wisconsin. The
      investigators propose studying the use of magnesium and lidocaine in a single syringe for
      pretreatment of propofol related pain on injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will involve little if any change from the typical induction of general
      anesthesia. Considering that lidocaine is routinely used for the induction of anesthesia, and
      that some anesthesia staff also inject magnesium prior to propofol, there will be little
      variation in the induction of anesthesia. Patients will be randomly assigned (by microsoft
      excel program providing a random number 1-4) to one of four groups:

        1. Lidocaine 50 mg in a 10 cc syringe

        2. Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe

        3. 0.9% saline in a 10 cc syringe

        4. Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe

      Study drugs will be prepared in identical syringes by the Pharmaceutical Research Center
      (PRC). Study personnel will receive a syringe labeled with the study number as well as a data
      collection sheet labeled with the study number. A 20 gauge angiocatheter will be inserted
      into the dorsum of the hand for IV fluids and medication administration. Subjects will be
      given preoperative 1-2 mg intravenous midazolam for sedation when the subject is en route to
      the operating room as is typically done at the discretion of the anesthesia provider caring
      for the patient. After instituting standard monitors and providing preoxygenation, the study
      drug will be injected. Twenty seconds later, 50 mg of propofol will be injected. Ten seconds
      after infusion of propofol, the subjects will then be asked a standard question about pain on
      injection &quot;Are you having pain at your IV site?&quot;. Any behavioral signs such as facial
      grimacing, arm withdrawal, or tears will be noted. Pain will be assessed using a four point
      scale: 0=no pain, 1=mild pain (pain reported only in response to questioning and without
      behavioral signs), 2=moderate pain (pain reported in response to questioning and accompanied
      by a behavioral sign, or pain reported spontaneously without questioning), 3=severe pain
      (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or
      tears). Study key personnel will do these pain assessments; the behavioral signs and
      self-reporting of pain will be recorded separate from one another. The induction of
      anesthesia will then by completed with the appropriate amount of propofol. Formally assessing
      pain following injection is not something that is standard care but all patients are
      currently warned prior to injection that they may experience some warmth or burning at the
      site of their intravenous line.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain With Injection of Propofol</measure>
    <time_frame>Approximately one minute following administration of propofol.</time_frame>
    <description>Following injection of the study drug, 50 mg of propofol will be injected. Ten seconds after propofol, subjects will be asked a standard question about pain. Behavioral signs will be noted. Pain will be assessed using a four point scale: 0=no pain, 1=mild pain (pain reported only in response to questioning and without behavioral signs), 2=moderate pain (pain reported in response to questioning and a behavioral sign, or pain reported without questioning), 3=severe pain (strong vocal response or behavioral response).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Pain Associated With Injection of Propofol.</measure>
    <time_frame>&lt; 1 minute.</time_frame>
    <description>Ten seconds following injection of propofol, subjects were asked &quot;Are you having pain at your IV site?&quot; Any behavioral signs were noted. Injection pain was assessed using the following four point scale: 0 = no pain; 1 = mild pain (pain reported only in response to questioning and without behavioral signs); 2 = moderate pain (pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously without questioning); and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>General Anesthesia</condition>
  <condition>Intravenous Anesthesia</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine 50 mg in a 10 cc syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine/Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline in a 10 cc syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_label>Lidocaine/Magnesium</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine/Magnesium</intervention_name>
    <description>We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.</description>
    <arm_group_label>Lidocaine/Magnesium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults American Society of Anesthesiologists (ASA) physical status 1 and 2
             patients selected for general anesthesia.

        Exclusion Criteria:

          -  age &lt; 18 years

          -  allergy to local anesthetics

          -  end stage renal disease

          -  pregnancy

          -  prisoners

          -  patients requiring a rapid sequence induction

          -  refusal to participate and patients already participating in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristopher M Schroeder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Johnson RA, Harper NJ, Chadwick S, Vohra A. Pain on injection of propofol. Methods of alleviation. Anaesthesia. 1990 Jun;45(6):439-42.</citation>
    <PMID>2200299</PMID>
  </results_reference>
  <results_reference>
    <citation>Yull DN, Barkshire KF, Dexter T. Pretreatment with ketorolac and venous occlusion to reduce pain on injection of propofol. Anaesthesia. 2000 Mar;55(3):284-7.</citation>
    <PMID>10671850</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang YW, Buerkle H, Lee TH, Lu CY, Lin CR, Lin SH, Chou AK, Muhammad R, Yang LC. Effect of pretreatment with ketorolac on propofol injection pain. Acta Anaesthesiol Scand. 2002 Sep;46(8):1021-4.</citation>
    <PMID>12190806</PMID>
  </results_reference>
  <results_reference>
    <citation>Ambesh SP, Dubey PK, Sinha PK. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study. Anesth Analg. 1999 Jul;89(1):197-9.</citation>
    <PMID>10389803</PMID>
  </results_reference>
  <results_reference>
    <citation>Apiliogullari S, Keles B, Apiliogullari B, Balasar M, Yilmaz H, Duman A. Comparison of diphenhydramine and lidocaine for prevention of pain after injection of propofol: a double-blind, placebo-controlled, randomized study. Eur J Anaesthesiol. 2007 Mar;24(3):235-8. Epub 2007 Jan 4.</citation>
    <PMID>17202008</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishiyama T, Kashimoto S, Oguchi T, Furuya A, Fukushima H, Kumazawa T. Clonidine-ephedrine combination reduces pain on injection of propofol and blunts hemodynamic stress responses during the induction sequence. J Clin Anesth. 2006 May;18(3):211-5.</citation>
    <PMID>16731324</PMID>
  </results_reference>
  <results_reference>
    <citation>Saadawy I, Ertok E, Boker A. Painless injection of propofol: pretreatment with ketamine vs thiopental, meperidine, and lidocaine. Middle East J Anaesthesiol. 2007 Oct;19(3):631-44. Erratum in: Middle East J Anesthesiol. 2008 Feb;19(4):919.</citation>
    <PMID>18044291</PMID>
  </results_reference>
  <results_reference>
    <citation>Aşik I, Yörükoğlu D, Gülay I, Tulunay M. Pain on injection of propofol: comparison of metoprolol with lidocaine. Eur J Anaesthesiol. 2003 Jun;20(6):487-9.</citation>
    <PMID>12803269</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghai B, Makkar JK, Bala I, Wig J. Effect of parecoxib pretreatment and venous occlusion on propofol injection pain: a prospective, randomized, double-blinded, placebo-controlled study. J Clin Anesth. 2010 Mar;22(2):88-92. doi: 10.1016/j.jclinane.2009.03.011.</citation>
    <PMID>20304348</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujii Y, Itakura M. Comparison of lidocaine, metoclopramide, and flurbiprofen axetil for reducing pain on injection of propofol in Japanese adult surgical patients: a prospective, randomized, double-blind, parallel-group, placebo-controlled study. Clin Ther. 2008 Feb;30(2):280-6. doi: 10.1016/j.clinthera.2008.02.018. Retraction in: Clin Ther. 2018 Apr 30;:.</citation>
    <PMID>18343266</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwak KH, Ha J, Kim Y, Jeon Y. Efficacy of combination intravenous lidocaine and dexamethasone on propofol injection pain: a randomized, double-blind, prospective study in adult Korean surgical patients. Clin Ther. 2008 Jun;30(6):1113-9. doi: 10.1016/j.clinthera.2008.05.019.</citation>
    <PMID>18640467</PMID>
  </results_reference>
  <results_reference>
    <citation>Agarwal A, Ansari MF, Gupta D, Pandey R, Raza M, Singh PK, Shiopriye, Dhiraj S, Singh U. Pretreatment with thiopental for prevention of pain associated with propofol injection. Anesth Analg. 2004 Mar;98(3):683-6, table of contents.</citation>
    <PMID>14980919</PMID>
  </results_reference>
  <results_reference>
    <citation>Borazan H, Erdem TB, Kececioglu M, Otelcioglu S. Prevention of pain on injection of propofol: a comparison of lidocaine with different doses of paracetamol. Eur J Anaesthesiol. 2010 Mar;27(3):253-7. doi: 10.1097/EJA.0b013e328330eca2.</citation>
    <PMID>19696679</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwak K, Kim J, Park S, Lim D, Kim S, Baek W, Jeon Y. Reduction of pain on injection of propofol: combination of pretreatment of remifentanil and premixture of lidocaine with propofol. Eur J Anaesthesiol. 2007 Sep;24(9):746-50. Epub 2007 Jan 30.</citation>
    <PMID>17261216</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayoğlu H, Altunkaya H, Ozer Y, Yapakçi O, Cukdar G, Ozkoçak I. Does dexmedetomidine reduce the injection pain due to propofol and rocuronium? Eur J Anaesthesiol. 2007 Jun;24(6):541-5. Epub 2007 Jan 23.</citation>
    <PMID>17241503</PMID>
  </results_reference>
  <results_reference>
    <citation>Memiş D, Turan A, Karamanlioğlu B, Süt N, Pamukçu Z. The use of magnesium sulfate to prevent pain on injection of propofol. Anesth Analg. 2002 Sep;95(3):606-8, table of contents.</citation>
    <PMID>12198045</PMID>
  </results_reference>
  <results_reference>
    <citation>Agarwal A, Dhiraj S, Raza M, Pandey R, Pandey CK, Singh PK, Singh U, Gupta D. Vein pretreatment with magnesium sulfate to prevent pain on injection of propofol is not justified. Can J Anaesth. 2004 Feb;51(2):130-3.</citation>
    <PMID>14766688</PMID>
  </results_reference>
  <results_reference>
    <citation>Gajraj NM, Nathanson MH. Preventing pain during injection of propofol: the optimal dose of lidocaine. J Clin Anesth. 1996 Nov;8(7):575-7.</citation>
    <PMID>8910180</PMID>
  </results_reference>
  <results_reference>
    <citation>Sasaki T, Okamura S, Kisara A, Ito M, Yogosawa K, Yagishita Y, Yogosawa T. Effect of lidocaine on pain caused by injection of propofol: comparison of three methods at two injection rates. J Anesth. 1999;13(1):14-6.</citation>
    <PMID>15235946</PMID>
  </results_reference>
  <results_reference>
    <citation>Tramèr MR, Glynn CJ. An evaluation of a single dose of magnesium to supplement analgesia after ambulatory surgery: randomized controlled trial. Anesth Analg. 2007 Jun;104(6):1374-9, table of contents.</citation>
    <PMID>17513629</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <results_first_submitted>April 20, 2012</results_first_submitted>
  <results_first_submitted_qc>May 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2012</results_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravenous Anesthesia</keyword>
  <keyword>General Anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between 6/2011 and 10/2011.</recruitment_details>
      <pre_assignment_details>We were able to consent 200 patients. The patients were distributed between the groups as follows, 39 patients in the control group, 38 patients in the lidocaine group, 44 patients in the magnesium group, and 37 patients in the magnesium/lidocaine group. Patients did not receive study drug if ASA score or peripheral IV inserted was not a 20 gauge.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Lidocaine 50 mg in a 10 cc syringe</description>
        </group>
        <group group_id="P2">
          <title>Magnesium</title>
          <description>Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe</description>
        </group>
        <group group_id="P3">
          <title>Lidocaine/Magnesium</title>
          <description>Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>0.9% saline in a 10 cc syringe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Lidocaine 50 mg in a 10 cc syringe</description>
        </group>
        <group group_id="B2">
          <title>Magnesium</title>
          <description>Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe</description>
        </group>
        <group group_id="B3">
          <title>Lidocaine/Magnesium</title>
          <description>Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>0.9% saline in a 10 cc syringe</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="158"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="15.3"/>
                    <measurement group_id="B2" value="44.4" spread="17.2"/>
                    <measurement group_id="B3" value="44.3" spread="16.2"/>
                    <measurement group_id="B4" value="45.3" spread="18.6"/>
                    <measurement group_id="B5" value="45.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain With Injection of Propofol</title>
        <description>Following injection of the study drug, 50 mg of propofol will be injected. Ten seconds after propofol, subjects will be asked a standard question about pain. Behavioral signs will be noted. Pain will be assessed using a four point scale: 0=no pain, 1=mild pain (pain reported only in response to questioning and without behavioral signs), 2=moderate pain (pain reported in response to questioning and a behavioral sign, or pain reported without questioning), 3=severe pain (strong vocal response or behavioral response).</description>
        <time_frame>Approximately one minute following administration of propofol.</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Pain Associated With Injection of Propofol.</title>
        <description>Ten seconds following injection of propofol, subjects were asked “Are you having pain at your IV site?” Any behavioral signs were noted. Injection pain was assessed using the following four point scale: 0 = no pain; 1 = mild pain (pain reported only in response to questioning and without behavioral signs); 2 = moderate pain (pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously without questioning); and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears).</description>
        <time_frame>&lt; 1 minute.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Lidocaine 50 mg in a 10 cc syringe</description>
          </group>
          <group group_id="O2">
            <title>Magnesium</title>
            <description>Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe</description>
          </group>
          <group group_id="O3">
            <title>Lidocaine/Magnesium</title>
            <description>Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>0.9% saline in a 10 cc syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Pain Associated With Injection of Propofol.</title>
          <description>Ten seconds following injection of propofol, subjects were asked “Are you having pain at your IV site?” Any behavioral signs were noted. Injection pain was assessed using the following four point scale: 0 = no pain; 1 = mild pain (pain reported only in response to questioning and without behavioral signs); 2 = moderate pain (pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously without questioning); and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="0.46"/>
                    <measurement group_id="O2" value="25" spread="0.5"/>
                    <measurement group_id="O3" value="15" spread="0.5"/>
                    <measurement group_id="O4" value="18" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Less than one minute following injection in intravenous propofol.</time_frame>
      <desc>Injection pain was assessed using the following four point scale:0=no pain;1=mild(pain reported only in response to questioning);2=moderate(pain reported in response to questioning and accompanied by a behavioral sign, or pain reported spontaneously);and 3=severe(strong vocal response or response accompanied by strong behavioral sign).</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Lidocaine 50 mg in a 10 cc syringe</description>
        </group>
        <group group_id="E2">
          <title>Magnesium</title>
          <description>Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe</description>
        </group>
        <group group_id="E3">
          <title>Lidocaine/Magnesium</title>
          <description>Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
          <description>0.9% saline in a 10 cc syringe</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain with injection of propofol</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Problems with designation of ASA score differing from that given by anesthesiologist, insertion of a 20 gauge angiocatheter into the dorsum of the hand and anesthesia plan changing (general to monitored) prior to going to the operating room.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kristopher Schroeder</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health, Department of Anesthesiology</organization>
      <phone>608-263-8100</phone>
      <email>kmschro1@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

